For the quarter ending 2025-09-30, MRKR had $7,128,007 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,998,662 | -8,461,748 |
| Stock-based compensation | 33,279 | 393,130 |
| Prepaid expenses and deposits | -151,865 | 794,872 |
| Other receivables | -9,182 | -672,368 |
| Related party payable | -328,316 | -1,053,869 |
| Accounts payable and accrued expenses | -603,224 | 513,917 |
| Deferred revenue | 0 | 1,352,975 |
| Net cash used in operating activities | -2,735,876 | -7,378,099 |
| Proceeds from issuance of common stock, net | 9,863,883 | - |
| Proceeds from exercise of warrants and stock options | 0 | 605 |
| Net cash provided by financing activities | 9,863,883 | 605 |
| Net decrease in cash, cash equivalents, and restricted cash | 7,128,007 | -7,377,494 |
| Cash and cash equivalents at beginning of period | 19,192,440 | - |
| Cash and cash equivalents at end of period | 18,942,953 | - |
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)